Literature DB >> 8708941

Detection of stable and active periodontitis sites by clinical assessment and gingival crevicular acute-phase protein levels.

E Adonogianaki1, J Mooney, D F Kinane.   

Abstract

The aim of the present study was to investigate whether incipient periodontal disease breakdown could be associated with changes in gingival crevicular fluid (GCF) acute-phase protein levels. In addition, the potential of clinical indices to act as predictors of significant attachment level (AL) change was investigated. AL measurements were taken at baseline and 3 months using the Florida Probe stent handpiece from a total of 384 sites in 38 patients. The average standard deviation of duplicate AL measurements was 0.423. When the tolerance method was used to detect significant AL change, 3.9% of the sites lost attachment. When a less stringent criterion of AL change of > or = 1 mm was used 9.9% of the sites lost attachment during the 3-month period. With the exception of probing depth, baseline clinical parameters failed to predict AL change. Fourteen active periodontitis sites that demonstrated significant attachment loss were paired to stable periodontitis sites within the same patient. The levels of four acute-phase proteins, namely alpha 2-macroglobulin (alpha 2-M), alpha 1-antitrypsin (alpha 1-AT), transferrin (TF) and lactoferrin (LF), and also albumin (Alb) were assessed in the same gingival crevicular fluid sample using sandwich ELISAs. Results were expressed either as ng/30 s and ng/microgram Alb. Acute-phase protein levels in GCF failed to differentiate between active and stable periodontitis sites at baseline. In conclusion, the degree of gingival inflammation of the tissues adjacent to the crevice/pocket seems to influence the levels of protease inhibitors and iron-binding proteins in GCF to a greater extent than probing attachment loss.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8708941     DOI: 10.1111/j.1600-0765.1996.tb00475.x

Source DB:  PubMed          Journal:  J Periodontal Res        ISSN: 0022-3484            Impact factor:   4.419


  7 in total

1.  Analysis of inorganic ions in gingival crevicular fluid as indicators of periodontal disease activity: A clinico-biochemical study.

Authors:  Arati C Koregol; Shobha P More; Sangamesh Nainegali; Nagaraj Kalburgi; Siddharth Verma
Journal:  Contemp Clin Dent       Date:  2011-10

2.  Application of Lactoferrin and α1-Antitrypsin in Gingival Retention Fluid to Diagnosis of Periodontal Disease.

Authors:  Ryosuke Koshi; Kazuhiko Kotani; Mariko Ohtsu; Naoto Yoshinuma; Naoyuki Sugano
Journal:  Dis Markers       Date:  2018-11-07       Impact factor: 3.434

3.  Does Periodontal Inflammation Affect Type 1 Diabetes in Childhood and Adolescence? A Meta-Analysis.

Authors:  Biagio Rapone; Massimo Corsalini; Ilaria Converti; Maria Teresa Loverro; Antonio Gnoni; Paolo Trerotoli; Elisabetta Ferrara
Journal:  Front Endocrinol (Lausanne)       Date:  2020-05-05       Impact factor: 5.555

4.  Identification and Modification of Porphyromonas gingivalis Cysteine Protease, Gingipain, Ideal for Screening Periodontitis.

Authors:  Kimito Hirai; Tomoko Yamaguchi-Tomikawa; Toru Eguchi; Hiroshi Maeda; Shogo Takashiba
Journal:  Front Immunol       Date:  2020-06-05       Impact factor: 7.561

5.  Usefulness of hemoglobin examination in gingival crevicular fluid during supportive periodontal therapy to diagnose the pre-symptomatic state in periodontal disease.

Authors:  Hiroshi Ito; Yukihiro Numabe; Shuichi Hashimoto; Sunao Uehara; Ya-Hsin Wu; Tomohisa Ogawa
Journal:  Clin Oral Investig       Date:  2020-06-15       Impact factor: 3.573

6.  The effect of periodontal treatment on C-reactive protein: A clinical study.

Authors:  Santosh Kumar; Samir Shah; Shilpa Budhiraja; Khushboo Desai; Chirag Shah; Dhaval Mehta
Journal:  J Nat Sci Biol Med       Date:  2013-07

Review 7.  Oral antimicrobial peptides: Types and role in the oral cavity.

Authors:  Zohaib Khurshid; Mustafa Naseem; Zeeshan Sheikh; Shariq Najeeb; Sana Shahab; Muhammad Sohail Zafar
Journal:  Saudi Pharm J       Date:  2015-03-06       Impact factor: 4.330

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.